Insights into the molecular pathogenesis of progression in multiple sclerosis: potential implications for future therapies.
about
Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeuticsLigation of the jugular veins does not result in brain inflammation or demyelination in miceStem cell therapy for central nerve system injuries: glial cells hold the keyConcise review: modeling multiple sclerosis with stem cell biological platforms: toward functional validation of cellular and molecular phenotypes in inflammation-induced neurodegenerationA computational analysis of protein-protein interaction networks in neurodegenerative diseases.Myeloperoxidase-targeted imaging of active inflammatory lesions in murine experimental autoimmune encephalomyelitis.Effect of optic neuritis on progressive axonal damage in multiple sclerosis patients.A novel unbiased proteomic approach to detect the reactivity of cerebrospinal fluid in neurological diseasesComparison of multifocal visual evoked potential, standard automated perimetry and optical coherence tomography in assessing visual pathway in multiple sclerosis patients.Multimodal coherent anti-Stokes Raman scattering microscopy reveals microglia-associated myelin and axonal dysfunction in multiple sclerosis-like lesions in miceAxonal loss in the retinal nerve fiber layer in patients with multiple sclerosis.Reversible neural stem cell niche dysfunction in a model of multiple sclerosis.Neural stem cells respond to stress hormones: distinguishing beneficial from detrimental stress.Application of multispectral imaging detects areas with neuronal myelin loss, without tissue labelling.Gelsolin decreases actin toxicity and inflammation in murine multiple sclerosis.Cell surface glycan engineering of neural stem cells augments neurotropism and improves recovery in a murine model of multiple sclerosis.Distinct functions of autoreactive memory and effector CD4+ T cells in experimental autoimmune encephalomyelitis.Prospects for neural stem cell-based therapies for neurological diseases.Radiopharmaceutical stem cell tracking for neurological diseases.Remyelinating strategies in multiple sclerosis.Regulation by glycogen synthase kinase-3 of inflammation and T cells in CNS diseasesEndogenous repair and development inspired therapy of neurodegeneration in progressive multiple sclerosis.Soluble vascular endothelial growth factor (VEGF) receptor-1 inhibits migration of human monocytic THP-1 cells in response to VEGF.Retinal nerve fiber layer atrophy is associated with physical and cognitive disability in multiple sclerosis.Elevated expression of granulocyte-macrophage colony-stimulating factor receptor in multiple sclerosis lesions.Pericytes modulate myelination in the central nervous system.Retinal measures correlate with cognitive and physical disability in early multiple sclerosis.Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis.The payer's perspective: What is the burden of MS and how should the patient's perspective be integrated in health technology assessment conducted for taking decisions on access to care and treatment?Natural history of secondary-progressive multiple sclerosis
P2860
Q24685475-1E2BAC7E-54EA-4D85-8DE4-86C72866D876Q27306416-B0DD37EB-C5DF-4203-9A6E-FFEA185E507FQ28394140-EC8D8897-34F9-4C82-A6B1-30517F24010CQ28649438-A5C152DA-C91A-4EF0-A025-ABB9D0739D63Q33345563-253DBD03-B962-400E-BD29-76D8C09B7FE5Q33708751-72821337-13B6-4025-88BD-535B6805C90DQ33814175-52442D16-7B88-4B2A-BBF7-08F9F73E4CF9Q33851008-5024C41B-3777-4D50-B0B9-9E91F0C4BD5FQ34104172-5F80107C-21D0-4DD8-8060-BB36958858B0Q34700833-B38C158F-AFA1-48C7-A319-A1A5C0259B94Q34771809-57BAE6A9-E8F3-4A3E-91C4-B83F81AD5D80Q34861360-FF3F9AAF-B645-4096-B03B-199833764CE5Q35167271-992E29D7-C52B-4A98-A170-CF3033DAD4B5Q35824842-A69CF20D-7A0B-4D30-B62D-2C4B16698221Q36129472-FB7E0257-F37B-4B12-B387-C34FB2F683E0Q36251782-713CD982-5B7E-4B88-BEB0-F66650B6D736Q36778241-C2CB9975-B597-4C8D-A772-A6A8819A557CQ36963218-49AA77B1-9709-4257-A7E6-820F64A47548Q38225145-6FB2DFB6-A016-4D93-A6B6-0A994B108AB5Q38261543-60C5B8B2-5960-435B-BE08-BD5477151D58Q38371329-1E19DDEC-E5C5-43B7-85F1-A7F98628C588Q38765008-BD935BBA-1C52-431F-B8AB-8DA4AC4B7AC9Q39559510-0C3BC17A-6743-4C2F-8E5C-87B44460B01EQ46523195-7B70A030-6728-4825-AC61-7D319778A6B8Q47228726-6B131519-0DE4-4928-80C4-25FB7F87A776Q47928247-06D91ED7-DBE9-4EF3-840E-6E96AC507078Q50593721-D7614238-78B3-44C4-B0C0-B9D7AD937046Q51449619-43651E7C-0D1A-4B68-8B2C-9293470F7B40Q52985191-674F5338-A152-4C53-8CD8-BEDFB5288A77Q59121739-19FFA8E3-7DB6-4962-B813-BF620E27E1F9
P2860
Insights into the molecular pathogenesis of progression in multiple sclerosis: potential implications for future therapies.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Insights into the molecular pa ...... ications for future therapies.
@ast
Insights into the molecular pa ...... ications for future therapies.
@en
type
label
Insights into the molecular pa ...... ications for future therapies.
@ast
Insights into the molecular pa ...... ications for future therapies.
@en
prefLabel
Insights into the molecular pa ...... ications for future therapies.
@ast
Insights into the molecular pa ...... ications for future therapies.
@en
P356
P1433
P1476
Insights into the molecular pa ...... ications for future therapies.
@en
P2093
Jaime Imitola
P356
10.1001/ARCHNEUR.63.1.25
P577
2006-01-01T00:00:00Z